Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 41, 2014, Pages 14776-14781

  Ammirante, Massimo ^a,b   Shalapour, Shabnam ^a,b   Kang, Youngjin ^a,b   Jamieson, Christina A M ^b   Karin, Michael ^a,b  

^a Laboratory of Gene Regulation and Signal Transduction   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Cancer; Cancer associated fibroblasts; Inflammation; Tumor microenvironment

Indexed keywords

ANDROGEN; CONNECTIVE TISSUE GROWTH FACTOR; CTGF PROTEIN, HUMAN; CXCL13 CHEMOKINE; CXCL13 PROTEIN, HUMAN; DEATH RECEPTOR 3; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PHOSPHODIESTERASE V INHIBITOR; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA;

ADENOCARCINOMA; ANIMAL; ANOXIA; CASTRATION RESISTANT PROSTATE CANCER; DISEASE COURSE; DRUG EFFECTS; HUMAN; MALE; METABOLISM; MYOFIBROBLAST; PATHOLOGY; PROSTATE; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ADENOCARCINOMA; ANDROGENS; ANIMALS; ANOXIA; CHEMOKINE CXCL13; CONNECTIVE TISSUE GROWTH FACTOR; DISEASE PROGRESSION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INSULIN-LIKE GROWTH FACTOR I; MALE; MICE, TRANSGENIC; MYOFIBROBLASTS; PHOSPHODIESTERASE 5 INHIBITORS; PROSTATE; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 25; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84907921199     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1416498111     Document Type: Article

References (55)

1. Jemal A, et al. (2011) Global cancer statistics. CA Cancer J Clin 61(2):69-90.
2. Hirano D, Hasegawa R, Satoh K, et al. (Apri 15, 2014) Prospective study on the relationship between clinical efficacy of secondary hormone therapy with flutamide and neuroendocrine differentiation in patients with relapsed prostate cancer after first line hormone therapy. Scand J Urol, doi:10.3109/21681805.2014.905633.
3. Beltran H, et al. (2012) Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol 30(36):e386-e389.
4. Beltran H, Rickman DS, Park K, et al. (2011) Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 1(6): 487-495.
5. Terry S, Beltran H (2014) The many faces of neuroendocrine differentiation in prostate cancer progression. Front Oncol 4:60.
6. Gueron G, DeSiervi A, Vazquez E (2012) Advanced prostate cancer: Reinforcing the strings between inflammation and the metastatic behavior. Prostate Cancer Prostatic Dis 15(3):213-221.
7. So A, Gleave M, Hurtado-Col A, Nelson C (2005) Mechanisms of the development of androgen independence in prostate cancer. World J Urol 23(1):1-9.
8. Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M (2010) B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 464(7286):302-305.
9. Woo JR, et al. (2014) Tumor infiltrating B-cells are increased in prostate cancer tissue. J Transl Med 12:30.
10. Luo JL, et al. (2007) Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature 446(7136):690-694.
11. Bhowmick NA, Neilson EG, Moses HL (2004) Stromal fibroblasts in cancer initiation and progression. Nature 432(7015):332-337.
12. Hanahan D, Coussens LM (2012) Accessories to the crime: Functions of cells recruited to the tumor microenvironment. Cancer Cell 21(3):309-322.
13. Kalluri R, Zeisberg M (2006) Fibroblasts in cancer. Nat Rev Cancer 6(5):392-401.
14. Shimoda M, Mellody KT, Orimo A (2010) Carcinoma-associated fibroblasts are a ratelimiting determinant for tumour progression. Semin Cell Dev Biol 21(1):19-25.
15. Dirat B, et al. (2011) Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res 71(7):2455-2465.
16. Erez N, Truitt M, Olson P, Arron ST, Hanahan D (2010) Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. Cancer Cell 17(2):135-147.
17. Cirri P, Chiarugi P (2011) Cancer associated fibroblasts: The dark side of the coin. Am J Cancer Res 1(4):482-497.
18. Räsänen K, Vaheri A (2010) Activation of fibroblasts in cancer stroma. Exp Cell Res 316(17):2713-2722.
19. Lee SB, Kalluri R (2010) Mechanistic connection between inflammation and fibrosis. Kidney Int Suppl (119):S22-S26.
20. LeBleu VS, et al. (2013) Origin and function of myofibroblasts in kidney fibrosis. Nat Med 19(8):1047-1053.
21. Grotendorst GR, Rahmanie H, Duncan MR (2004) Combinatorial signaling pathways determine fibroblast proliferation and myofibroblast differentiation. FASEB J 18(3): 469-479.
22. Velarde MC, Demaria M, Campisi J (2013) Senescent cells and their secretory phenotype as targets for cancer therapy. Interdiscip Top Gerontol 38:17-27.
23. Sun Y, et al. (2012) Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med 18(9): 1359-1368.
24. Ansel KM, et al. (2000) A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 406(6793):309-314.
25. Singh S, et al. (2009) Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion. Cancer Lett 283(1):29-35.
26. Singh S, Singh R, Singh UP, et al. (2009) Clinical and biological significance of CXCR5 expressed by prostate cancer specimens and cell lines. Int J Cancer 125(10):2288-2295.
27. Watson PA, et al. (2005) Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. Cancer Res 65(24):11565-11571.
28. Kraman M, et al. (2010) Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 330(6005):827-830.
29. Chen H, Yang WW, Wen QT, Xu L, Chen M (2009) TGF-beta induces fibroblast activation protein expression; fibroblast activation protein expression increases the proliferation, adhesion, and migration of HO-8910PM [corrected]. Exp Mol Pathol 87(3): 189-194.
30. Loeffler M, Krüger JA, Niethammer AG, Reisfeld RA (2006) Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 116(7):1955-1962.
31. Inman GJ, et al. (2002) SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 62(1):65-74.
32. Tone Y, et al. (2008) Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat Immunol 9(2):194-202.
33. Stopa M, et al. (2000) Participation of Smad2, Smad3, and Smad4 in transforming growth factor beta (TGF-beta)-induced activation of Smad7. THE TGF-beta response element of the promoter requires functional Smad binding element and E-box sequences for transcriptional regulation. J Biol Chem 275(38):29308-29317.
34. Roozendaal R, Mebius RE (2011) Stromal cell-immune cell interactions. Annu Rev Immunol 29:23-43.
35. Guo S, Dipietro LA (2010) Factors affecting wound healing. J Dent Res 89(3):219-229.
36. Ryan HE, Lo J, Johnson RS (1998) HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 17(11):3005-3015.
37. Higgins DF, et al. (2004) Hypoxic induction of Ctgf is directly mediated by Hif-1. Am J Physiol Renal Physiol 287(6):F1223-F1232.
38. Zhang H, et al. (2003) Cellular response to hypoxia involves signaling via Smad proteins. Blood 101(6):2253-2260.
39. Schäffer L, et al. (2003) Oxygen-regulated expression of TGF-beta 3, a growth factor involved in trophoblast differentiation. Placenta 24(10):941-950.
40. Basu RK, et al. (2011) Interdependence of HIF-1α and TGF-β/Smad3 signaling in normoxic and hypoxic renal epithelial cell collagen expression. Am J Physiol Renal Physiol 300(4):F898-F905.
41. Rosen RC, McKenna KE (2002) PDE-5 inhibition and sexual response: Pharmacological mechanisms and clinical outcomes. Annu Rev Sex Res 13:36-88.
42. Zenzmaier C, et al. (2010) Attenuated proliferation and trans-differentiation of prostatic stromal cells indicate suitability of phosphodiesterase type 5 inhibitors for prevention and treatment of benign prostatic hyperplasia. Endocrinology 151(8): 3975-3984.
43. Zenzmaier C, et al. (2012) Phosphodiesterase type 5 inhibition reverts prostate fibroblast-to-myofibroblast trans-differentiation. Endocrinology 153(11):5546-5555.
44. Nandi JS, Nair KG, Deo S (1980) Inhibition cAMP-phosphodiesterase in the rat heart by pentoxifylline-a new xanthine derivative. Adv Myocardiol 1:359-365.
45. Greenberg NM, et al. (1995) Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92(8):3439-3443.
46. Qi J, et al. (2010) Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell 18(1):23-38.
47. Xing F, Saidou J, Watabe K (2010) Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci (Landmark Ed) 15:166-179.
48. Legler DF, et al. (1998) B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med 187(4):655-660.
49. Rundqvist H, Johnson RS (2010) Hypoxia and metastasis in breast cancer. Curr Top Microbiol Immunol 345:121-139.
50. Dean JP, Nelson PS (2008) Profiling influences of senescent and aged fibroblasts on prostate carcinogenesis. Br J Cancer 98(2):245-249.
51. Paris F, et al. (2001) Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293(5528):293-297.
52. Weidemann A, Johnson RS (2008) Biology of HIF-1alpha. Cell Death Differ 15(4): 621-627.
53. Li B, Wang JH (2011) Fibroblasts and myofibroblasts in wound healing: Force generation and measurement. J Tissue Viability 20(4):108-120.
54. Peduto L, et al. (2009) Inflammation recapitulates the ontogeny of lymphoid stromal cells. J Immunol 182(9):5789-5799.
55. Cantrell MA, Baye J, Vouri SM (2013) Tadalafil: A phosphodiesterase-5 inhibitor for benign prostatic hyperplasia. Pharmacotherapy 33(6):639-649.